GlobeNewswire·Nov 9, 2026, 12:30 PM ET

Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder

Altimmune presented positive RECLAIM Phase 2 results showing pemvidutide significantly reduced heavy drinking days by 1.45 days per week versus placebo (p=0.0014) in adults with moderate-to-severe alcohol use disorder (AUD).
42.2% of pemvidutide-treated patients achieved zero heavy drinking days compared to 17.4% with placebo, while abstinence rates increased to 38.9% versus 20.5%.
Treatment with pemvidutide resulted in a 153.4 ng/mL decrease in PEth levels versus a 22.0 ng/mL increase with placebo, confirming reduced alcohol intake (p<0.0001).
Participants receiving pemvidutide experienced an 8.7% mean weight loss compared to 0.4% with placebo, and 50% with elevated baseline liver fibrosis risk achieved normalization versus 17% with placebo.
The drug demonstrated a generally favorable tolerability profile with adverse events primarily being mild-to-moderate, though gastrointestinal issues like nausea (44%) \& vomiting (18%) were more common than in the placebo group.
Altimmune is scheduled to hold an End-of-Phase 2 meeting with the FDA in December 2026 to discuss the design of the Phase 3 registrational program for AUD.
Additional IMPACT Phase 2b data showed concurrent reductions in liver fibrosis markers, liver fat, \& ALT levels in patients with MASH, with no severe gastrointestinal adverse events reported.
Pemvidutide is an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist that has received Fast Track designations from the FDA for both MASH \& AUD.